Page 1178 - Basic _ Clinical Pharmacology ( PDFDrive )

1164 SECTION X Special Topics

TABLE 66–1 Important drug interactions.

Drug or Properties Promoting
Drug Group Drug Interaction Clinically Documented Interactions
Cisapride (cont.) Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the metabolism of
cisapride.
Nefazodone: [NP] Decreased metabolism of cisapride by CYP3A4.
Ritonavir: [P] Decreased metabolism of cisapride.
Selective serotonin reuptake inhibitors (SSRIs): [NP] Fluvoxamine reduces cisapride
metabolism.
See also Azole antifungals.
Colchicine Susceptible to changes in CYP3A4 Amiodarone: [NP] Decreased colchicine metabolism and transport. Expect similar
metabolism and P-glycoprotein interactions with dronedarone.
transport.
Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine, fosamprenavir,
indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir inhibit the metabolism
of colchicine.
Carbamazepine: [P] Increased metabolism of colchicine.
Cobicistat: [P] Decreased metabolism of colchicine.
Conivaptan: [P] Decreased metabolism of colchicine.
Cyclosporine: [P] Decreased colchicine elimination.
Kinase inhibitors: [P] Decreased metabolism of colchicine with ceritinib, dasatinib,
imatinib, idelalisib, and lapatinib.
Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the metabolism of
colchicine.
Nefazodone: [NE] Decreased colchicine metabolism.
Rifampin: [P] Increased colchicine metabolism.
St. John’s wort: [NP] Increased colchicine metabolism.
See also Azole antifungals; Calcium channel blockers.
Cyclosporine Susceptible to induction and Aminoglycosides: [NE] Possible additive nephrotoxicity.
inhibition of elimination by CYP3A4
and P-glycoprotein. (Tacrolimus and Amphotericin B: [NE] Possible additive nephrotoxicity.
sirolimus appear to have similar Cidofovir: [NE] Possible additive nephrotoxicity.
interactions.)
Drugs that may increase cyclosporine effect:
Amiodarone: [P] Decreased cyclosporine elimination. Expect similar interaction with
dronedarone.
Androgens: [NE] Increased serum cyclosporine concentration.
Antivirals: [P] Amprenavir, atazanavir, boceprevir, darunavir, delavirdine,
fosamprenavir, indinavir, nelfinavir, ritonavir, saquinavir, simeprevir, and telaprevir
inhibit the elimination of cyclosporine.
Cobicistat: [P] Decreased cyclosporine elimination.
Conivaptan: [P] Decreased cyclosporine elimination.
Kinase inhibitors: [P] Decreased metabolism of cyclosporine with ceritinib, dasatinib,
imatinib, idelalisib, and lapatinib. Cyclosporine reduces metabolism of kinase inhibitors.
Macrolide antibiotics: [P] Clarithromycin and erythromycin inhibit the elimination of
cyclosporine.
Nefazodone: [P] Decreased cyclosporine metabolism.
Quinupristin: [P] Decreased cyclosporine metabolism.
E, Expected; HP, Highly predictable. Interaction occurs in almost all patients receiving the interacting combination; P, Predictable. Interaction occurs in most patients receiving the
combination; NP, Not predictable. Interaction occurs only in some patients receiving the combination; NE, Not established. Insufficient data available on which to base estimate
of predictability.
(continued )